Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY ® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials.
Tsutomu TakeuchiYukihiro ChinoMasafumi KawanishiMegumi NakanishiHirotaka WataseYoko ManoYuri SatoSaeko UchidaYoshiya TanakaPublished in: Arthritis research & therapy (2023)
JapicCTI, OHZORA trial: JapicCTI-184029, registration date July 9, 2018; NATSUZORA trial: JapicCTI-184031, registration date July 9, 2018.